The Ministry of Health and Welfare will be the first to recognize the 3-drug combination benefit for diabetes treatment with SGLT-2 inhibition mechanism from April and expand the scope of the 2-drug combination benefit compared to the previous one.

Specifically, 'Metformin + SGLT-2 inhibitor + DPP-4 inhibitor' and 'Metformin + SGLT-2 inhibitor + TZD-type drugs' are covered by health insurance benefits when 3 drugs are prescribed together, and sulfonylurea (SU)-type drugs and When using SGLT-2 inhibitors together, the number of covered drugs will be increased from the current one to four. In the case of insulin injection and SGLT-2 inhibitor combination therapy, the number of covered drugs will be expand